Colorectal cancer is among the most common malignant tumor types and the second leading cause of tumor-related deaths worldwide. Tumor necrosis factor α-induced protein 8-like protein 2 (TIPE2) is a ...

Bombshell at RENK! Order intake is exploding! Revenue and earnings are also already up significantly. After Rheinmetall and ...

An off-the-shelf cancer vaccine that targets KRAS mutations induced T-cell responses and was associated with impressive ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

Bayer has inked a global licensing deal with Kumquat Biosciences for a KRAS G12D cancer drug, allowing Phase 1a trials to be ...

With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

Kumquat, based in San Diego, received US Food and Drug Administration clearance of its investigational new drug application for the KRAS G12D inhibitor in July. The firm will be responsible for ...

The vaccine ELI-002 2P showed favorable relapse-free survival and overall survival in patients with pancreatic and colorectal ...